Recent Research Analysts’ Ratings Updates for Arvinas (ARVN)

A number of research firms have changed their ratings and price targets for Arvinas (NASDAQ: ARVN):

• 5/13/2026 – Arvinas had its price target raised by Barclays PLC from $18.00 to $20.00. They now have an “overweight” rating on the stock.
• 5/13/2026 – Arvinas had its price target raised by BTIG Research from $16.00 to $18.00. They now have a “buy” rating on the stock.
• 5/4/2026 – Arvinas had its price target raised by Citigroup Inc. from $21.00 to $24.00. They now have a “buy” rating on the stock.
• 4/27/2026 – Arvinas was downgraded by Zacks Research from “hold” to “strong sell”.
• 4/10/2026 – Arvinas had its “sell (d-)” rating reaffirmed by Weiss Ratings.
• 3/19/2026 – Arvinas had its price target raised by Citigroup Inc. from $18.00 to $21.00. They now have a “buy” rating on the stock.
• 3/19/2026 – Arvinas had its price target raised by BTIG Research from $14.00 to $16.00. They now have a “buy” rating on the stock.

Insider Transactions at Arvinas

In related news, insider Noah Berkowitz sold 11,108 shares of the business’s stock in a transaction on Monday, May 11th. The shares were sold at an average price of $9.94, for a total value of $110,413.52. Following the completion of the transaction, the insider directly owned 191,395 shares in the company, valued at $1,902,466.30. The trade was a 5.49% decrease in their position. The transaction was disclosed in a document filed with the SEC, which is available at the SEC website. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Also, Director Briggs Morrison purchased 20,000 shares of Arvinas stock in a transaction that occurred on Friday, March 6th. The stock was acquired at an average cost of $13.40 per share, with a total value of $268,000.00. Following the acquisition, the director directly owned 96,021 shares in the company, valued at $1,286,681.40. This trade represents a 26.31% increase in their position. The disclosure for this purchase is available in the SEC filing. Over the last 90 days, insiders sold 81,449 shares of company stock worth $945,574. Insiders own 7.30% of the company’s stock.

Arvinas, Inc (NASDAQ: ARVN) is a biopharmaceutical company focused on the development of therapies based on targeted protein degradation. Utilizing its proprietary proteolysis-targeting chimera (PROTAC®) platform, Arvinas aims to selectively eliminate disease-causing proteins rather than merely inhibit their activity. This novel approach has the potential to address a range of diseases, including oncology, neurodegeneration and inflammation, by harnessing the body’s natural protein-recycling systems.

The company’s most advanced clinical candidates address hormone-driven cancers.